Linerixibat (formerly known as GSK2330672; GSK-2330672) is a novel, highly potent and nonabsorbable inhibitor of ASBT (apical sodium-dependent bile acid transporter) under development for cholestatic pruritus in primary biliary cholangitis.

Elobixibat (also known as AZD-7806, AJG-533 and A 3309) is a novel, potent and first-in-class ileal bile acid transporter (IBAT) inhibitor with IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT.

Odevixibat (formerly known as A-4250; AZD-8294; A-4250; AR-H 064974; Bylvay) is a novel, potent and orally bioavailable inhibitor of ileal bile acid transporter (IBAT) with the potential to be used for the treatment of primary biliary cirrhosis.